Keybank National Association OH boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 2.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 14,635 shares of the company’s stock after acquiring an additional 419 shares during the quarter. Keybank National Association OH’s holdings in Zoetis were worth $913,000 at the end of the most recent quarter.
Several other institutional investors have also recently made changes to their positions in ZTS. Assetmark Inc. lifted its holdings in shares of Zoetis by 4.6% during the 1st quarter. Assetmark Inc. now owns 1,918 shares of the company’s stock valued at $102,000 after buying an additional 85 shares during the last quarter. Guardian Life Insurance Co. of America lifted its holdings in shares of Zoetis by 0.7% during the 1st quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock valued at $102,000 after buying an additional 13 shares during the last quarter. Point72 Asia Hong Kong Ltd acquired a new stake in shares of Zoetis during the 1st quarter valued at about $111,000. Advisory Services Network LLC acquired a new stake in shares of Zoetis during the 1st quarter valued at about $112,000. Finally, First Interstate Bank lifted its holdings in shares of Zoetis by 3.5% during the 1st quarter. First Interstate Bank now owns 2,250 shares of the company’s stock valued at $120,000 after buying an additional 76 shares during the last quarter. Institutional investors and hedge funds own 93.31% of the company’s stock.
Shares of Zoetis Inc. (ZTS) traded down 0.26% during mid-day trading on Friday, reaching $65.08. The company had a trading volume of 602,474 shares. The firm’s 50 day moving average is $62.20 and its 200-day moving average is $59.31. The stock has a market capitalization of $31.83 billion, a P/E ratio of 36.79 and a beta of 1.02. Zoetis Inc. has a 12-month low of $46.86 and a 12-month high of $65.83.
Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.53. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The business had revenue of $1.27 billion during the quarter, compared to analyst estimates of $1.27 billion. During the same period in the prior year, the business posted $0.49 earnings per share. The company’s revenue was up 5.0% on a year-over-year basis. On average, analysts expect that Zoetis Inc. will post $2.34 earnings per share for the current fiscal year.
ZTS has been the subject of several research reports. Cantor Fitzgerald set a $75.00 price target on Zoetis and gave the company a “buy” rating in a report on Monday, August 14th. Stifel Nicolaus reissued a “buy” rating and issued a $65.00 price objective on shares of Zoetis in a research note on Friday, September 1st. Argus reissued a “buy” rating and issued a $69.00 price objective (up from $60.00) on shares of Zoetis in a research note on Tuesday, May 30th. CL King initiated coverage on Zoetis in a research note on Friday, May 26th. They issued a “buy” rating and a $71.00 price objective on the stock. Finally, Deutsche Bank AG reissued a “buy” rating and issued a $65.00 price objective (up from $62.00) on shares of Zoetis in a research note on Monday, July 17th. One research analyst has rated the stock with a sell rating, five have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $65.44.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with our FREE daily email newsletter.